1st-line treatment of patients with high-grade non-Hodgkin's lymphoma: Similar effectiveness with R-CHOP-14 or R-CHOP-21 Data from the German prospective TLN Registry

被引：0
|
作者：
Knauf, W. [1 ]
Abenhardt, W. [2 ]
Mohm, J. [3 ]
Rauh, J. [4 ]
Grugel, R. [5 ]
Harde, J. [5 ]
Jaenicke, M. [5 ]
Marschner, N. [6 ]
机构：
[1] Onkol Gemeinschaftspraxis, Frankfurt, Germany
[2] Munchner Onkol Praxis Elisenhof, Munich, Germany
[3] Onkol Gemeinschaftspraxis, Dresden, Germany
[4] Fachinternist Gemeinschaftspraxis U Therapiezentr, Witten, Germany
[5] iOMEDICO, Freiburg, Germany
[6] Praxis Interdisziplinare Onkol & Hamatol, Freiburg, Germany
来源：
Oncology Research and Treatment | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V75
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF BENDAMUSTINE-RITUXIMAB (BEN-R) VERSUS R-CHOP FOR THE FIRST LINE TREATMENT OF PATIENTS WITH INDOLENT NON HODGKIN'S LYMPHOMA (INHL) IN COLOMBIA
    Wehler, E. A.
    Kowal, S.
    Ariza, J. G.
    Zambrano, C.
    de Anda, J. A.
    Anaya, P.
    Munakata, J.
    Gonzalez, L.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A818 - A819
  • [22] Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Pfreundschuh, Michael
    Held, Gerhard
    Zeynalova, Samira
    Poeschel, Viola
    Viardot, Andreas
    Haenel, Matthias
    Keller, Ulrich
    Reiser, Marcel
    Loeffler, Markus
    Murawski, Niels
    [J]. BLOOD, 2011, 118 (21) : 272 - 273
  • [23] Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (vol 32, pg 4127, 2014)
    Pfreundschuh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1991 - 1991
  • [24] A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study
    Giles, FJ
    Shan, JQ
    Advani, SH
    Akan, H
    Aydogdu, I
    Aziz, Z
    Azim, HA
    Bapsy, PP
    Buyukkececi, F
    Chaimongkol, B
    Chen, PM
    Cheong, SK
    Ferhanoglu, B
    Hamza, R
    Khalid, HM
    Intragumtornchai, T
    Kim, SW
    Kim, SY
    Koc, H
    Kumar, L
    Kumar, R
    Lei, KI
    Lekhakula, A
    Muthalib, A
    Patel, M
    Poovalingam, VP
    Prayoonwiwat, W
    Rana, F
    Reksodiputro, AH
    Ruff, P
    Sagar, TG
    Schwarer, AP
    Song, HS
    Suh, CW
    Suharti, C
    Supindiman, I
    Tee, GY
    Thamprasit, T
    Villalon, AH
    Wickham, NR
    Wong, JE
    Yalcin, A
    Jootar, S
    [J]. LEUKEMIA & LYMPHOMA, 2000, 40 (1-2) : 95 - 103
  • [25] Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    Wunderlich, A
    Kloess, M
    Reiser, M
    Rudolph, C
    Truemper, L
    Bittner, S
    Schmalenberg, H
    Schmits, R
    Pfreundschuh, M
    Loeffler, M
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (06) : 881 - 893
  • [26] CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma:: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
    Tirelli, U
    Errante, D
    Van Glabbeke, M
    Teodorovic, I
    Kluin-Nelemans, JC
    Thomas, J
    Bron, D
    Rosti, G
    Somers, R
    Zagonel, V
    Noordijk, EM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 27 - 34
  • [27] Dose-dense rituximab improves outcome of elderly patients with poor-prognosis Diffuse Large B-cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the german high-grade non-hodgkin lymphoma study group (DSHNHL)
    Pfreundschuh, M.
    Zeynalova, S.
    Poeschel, V.
    Haenel, M.
    Schmitz, N.
    Hensel, M.
    Reiser, M.
    Loeffler, M.
    Schubert, J.
    [J]. ONKOLOGIE, 2008, 31 : 118 - +
  • [28] Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
    Pfreundschuh, Michael
    Zeynalova, Samira
    Poeschel, Viola
    Haenel, Mathias
    Schmitz, Norbert
    Hensel, Manfred
    Reiser, Marcel
    Loeffler, Markus
    Schubert, Joerg
    [J]. BLOOD, 2007, 110 (11) : 243A - 243A
  • [29] CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Boehme, Volkmar
    Schmitz, Norbert
    Zeynalova, Samira
    Loeffler, Markus
    Pfreundschuh, Michael
    [J]. BLOOD, 2009, 113 (17) : 3896 - 3902
  • [30] Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab:: Results of the DENSE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
    Pfreundschuh, M.
    Zeynalova, S.
    Poeschel, V.
    Haenel, M.
    Schmitz, N.
    Ho, A. D.
    Reiser, M.
    Loeffler, M.
    Schubert, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 99 - 100
12345